Literature DB >> 31632554

Mechanism of GPER promoting proliferation, migration and invasion of triple-negative breast cancer cells through CAF.

Kaihua Yang1, Yufeng Yao2.   

Abstract

Triple-negative breast cancer (TNBC) is an important histological subtype of breast cancer. Abnormal GPER expression has been reported in human breast cancer. However, the functional mechanism of GPER through carcinoma-associated fibroblast (CAF) in TNBC needed further investigations. The proliferation and cycle progression of the MDA-MB-231 cells were respectively analyzed by CCK-8 assay and flow cytometry, while cell migration and invasion were examined by wound healing assay and transwell assay. GPER expression in TNBC tissues and MDA-MB-231 cells was investigated by RT-qPCR, western blotting and immunohistochemistry. Collagen-1 was measured using ELISA. In addition, the role of GPER through CAF was investigated through cells were transfected with GPER interference plasmid and treated with GPER agonist, respectively. The transfection effects were verified by RT-qPCR. The results demonstrated that CAF could promote proliferation, migration and invasion of MDA-MB-231 cells compared with normal fibroblast (NF). GPER expression was decreased in TNBC tissues and MDA-MB-231 cells in comparison with the adjacent normal tissues and MCF-10A cells. GPER expression could affect the expression of Coll-1 in CAF. Downregulation of GPER inhibited Coll-1 expression in CAF, thereby inducing the decrease of cell proliferation, arrest of S phase and suppression of migration and invasion of MDA-MB-231 cells, while GPER agonist could be resulted in the opposite effects. In conclusion, the present data demonstrated that GPER promoted proliferation, migration and invasion of TNBC cells through CAF. Furthermore, GPER expression was positively related to the prognosis of TNBC. AJTR
Copyright © 2019.

Entities:  

Keywords:  G protein coupled receptor (GPER); TNBC; carcinoma-associated fibroblast (CAF); invasion; migration; proliferation

Year:  2019        PMID: 31632554      PMCID: PMC6789253     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  28 in total

Review 1.  Triple-negative breast cancer: disease entity or title of convenience?

Authors:  Lisa Carey; Eric Winer; Giuseppe Viale; David Cameron; Luca Gianni
Journal:  Nat Rev Clin Oncol       Date:  2010-09-28       Impact factor: 66.675

2.  GPER in CAFs regulates hypoxia-driven breast cancer invasion in a CTGF-dependent manner.

Authors:  Juan Ren; Hui Guo; Huili Wu; Tao Tian; Danfeng Dong; Yuelang Zhang; Yanxia Sui; Yong Zhang; Dongli Zhao; Shufeng Wang; Zongfang Li; Xiaozhi Zhang; Rui Liu; Jianshneg Qian; Hongxia Wei; Wenjun Jiang; Ya Liu; Yi Li
Journal:  Oncol Rep       Date:  2015-02-03       Impact factor: 3.906

Review 3.  GPER is involved in the functional liaison between breast tumor cells and cancer-associated fibroblasts (CAFs).

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  J Steroid Biochem Mol Biol       Date:  2017-02-27       Impact factor: 4.292

Review 4.  New prognostic histological parameter of invasive ductal carcinoma of the breast: clinicopathological significance of fibrotic focus.

Authors:  T Hasebe; K Mukai; H Tsuda; A Ochiai
Journal:  Pathol Int       Date:  2000-04       Impact factor: 2.534

Review 5.  The G-protein-coupled estrogen receptor GPER in health and disease.

Authors:  Eric R Prossnitz; Matthias Barton
Journal:  Nat Rev Endocrinol       Date:  2011-08-16       Impact factor: 43.330

6.  Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression.

Authors:  Edward J Filardo; Carl T Graeber; Jeffrey A Quinn; Murray B Resnick; Dilip Giri; Ronald A DeLellis; Margaret M Steinhoff; Edmond Sabo
Journal:  Clin Cancer Res       Date:  2006-11-01       Impact factor: 12.531

7.  p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.

Authors:  Manran Liu; Mathew C Casimiro; Chenguang Wang; L Andrew Shirley; Xuanmao Jiao; Sanjay Katiyar; Xiaoming Ju; Zhiping Li; Zuoren Yu; Jie Zhou; Michael Johnson; Paolo Fortina; Terry Hyslop; Jolene J Windle; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-26       Impact factor: 11.205

8.  GPER Mediates Non-Genomic Effects of Estrogen.

Authors:  Marco Pupo; Marcello Maggiolini; Anna Maria Musti
Journal:  Methods Mol Biol       Date:  2016

9.  What does an orphan G-protein-coupled receptor have to do with estrogen?

Authors:  James M Rae; Michael D Johnson
Journal:  Breast Cancer Res       Date:  2005-09-29       Impact factor: 6.466

10.  GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment.

Authors:  Ernesto Cortes; Muge Sarper; Benjamin Robinson; Dariusz Lachowski; Antonios Chronopoulos; Stephen D Thorpe; David A Lee; Armando E Del Río Hernández
Journal:  EMBO Rep       Date:  2018-12-11       Impact factor: 9.071

View more
  4 in total

1.  Cytoplasmic G Protein-Coupled Estrogen Receptor 1 as a Prognostic Indicator of Breast Cancer: A Meta-Analysis.

Authors:  Duo Zhang; Jinpeng Wang; Hong Chen; Shunchao Yan
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

2.  Thioridazine hydrochloride: an antipsychotic agent that inhibits tumor growth and lung metastasis in triple-negative breast cancer via inducing G0/G1 arrest and apoptosis.

Authors:  Yanlin Song; Lu Li; Jiao Chen; Hongli Chen; Bomiao Cui; Yun Feng; Ping Zhang; Qiangsheng Zhang; Yong Xia; Min Luo
Journal:  Cell Cycle       Date:  2020-12-14       Impact factor: 4.534

Review 3.  ERα, A Key Target for Cancer Therapy: A Review.

Authors:  Yanfang Liu; Hong Ma; Jing Yao
Journal:  Onco Targets Ther       Date:  2020-03-11       Impact factor: 4.147

Review 4.  G Protein-Coupled Estrogen Receptor in Cancer and Stromal Cells: Functions and Novel Therapeutic Perspectives.

Authors:  Richard A Pepermans; Geetanjali Sharma; Eric R Prossnitz
Journal:  Cells       Date:  2021-03-17       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.